Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CB2201 for adult upper limb spasticity
CTR20261134Phase 2Active
- Sponsor
- Ruoyi Biotech
- Start
- Mar 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of CB2201 in upper extremity spasticity, sponsored by Ruoyi Biotech. Started Mar 2026; status: active.
02
Drugs
CB2201
03
Conditions
upper extremity spasticity
Beyond the preview
Go deeper on CTR20261134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261134.